9.47

1.46% -0.14

After Hours: 9.50 0.03 +0.32%

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $9.47, with a volume of 334.47K. It is down -1.46% in the last 24 hours and up +7.61% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Previous Close:

$9.61

Open:

$9.59

24h Volume:

334.47K

Relative Volume:

1.76

Market Cap:

$458.61M

Revenue:

$62.02M

Net Income/Loss:

$-45.65M

P/E Ratio:

0.8336

EPS:

11.36

Net Cash Flow:

$-9.60M

1W Performance:

-0.53%

1M Performance:

+7.61%

6M Performance:

+5.46%

1Y Performance:

-8.68%

1-Day Range:

$9.37

$9.75

1-Week Range:

$9.37

$10.10

52-Week Range:

$7.44

$11.71

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TBPH's Discussions on Twitter

Compare TBPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TBPH	9.47	458.61M	62.02M	-45.65M	-9.60M	11.36
VRTX	450.97	116.38B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	82.09B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.14B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.25B	3.30B	-501.07M	1.03B	11.54

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

Nov 21, 2024

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Nov 21, 2024

Nov 20, 2024

Multiple System Atrophy Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma - The Globe and Mail

Nov 20, 2024

Theravance Biopharma to Present at Evercore HealthCONx Conference | TBPH Stock News - StockTitan

Nov 20, 2024

Madison Avenue Partners, LP Expands Stake in Theravance Biopharm - GuruFocus.com

Nov 14, 2024

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 14, 2024

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares - Investing.com India

Nov 13, 2024

Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com - Investing.com Canada

Nov 13, 2024

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat

Nov 13, 2024